OSLO, Norway, Oct. 1, 2019 /PRNewswire/ -- Nordic Nanovector
ASA (OSE: NANO) announces the appointment of Dr Gabriele Elbl as Vice President Global
Regulatory Affairs. Dr Elbl is a pharmacist with more than 20
years' experience working in small and large pharmaceutical
companies and at the European Medicines Agency (EMA). She brings
expertise in all regulatory aspects of pharmaceutical development
and submission procedures for biologicals and small molecules in
Europe and in the US with focus on
oncology and haematologic malignancies.
Dr Elbl will join Nordic Nanovector on 1
November 2019 from Mundipharma EDO, where she was Global
Head of Regulatory Affairs Oncology. Prior to this she held senior
leadership roles in global regulatory affairs at MorphoSys, Wilex
and Sanofi-Winthrop (part of Sanofi).
Dr. Elbl is a German citizen and holds a Ph.D. from the
Institute of Pharmaceutical Biology from the
Ludwig-Maximilians-University in Munich,
Germany.
Eduardo Bravo, Nordic
Nanovector's Chief Executive Officer, said, "Gabriele is an
important hire for Nordic Nanovector, bringing significant valuable
expertise to the senior management team. She will play a pivotal
role in refining and executing our regulatory strategy for
Betalutin® in non-Hodgkin's lymphoma. We are pleased to welcome
Gabriele to the team."
Gabriele Elbl commented: "I am
delighted to join Nordic Nanovector at this important time as we
look to accelerate the preparations for the regulatory filings for
Betalutin®, both in the US and Europe. As a single administration treatment,
this novel targeted radioimmunotherapy offers a clearly
differentiated therapy option for patients with non-Hodgkin's
lymphoma. I look forward to bringing my knowledge and making a
contribution to Nordic Nanovector during this exciting phase of its
development."
For further information, please contact:
IR enquiries
Malene Brondberg
VP Investor Relations and Corporate Communications
Cell: +44-7561-431-762
Email: ir@nordicnanovector.com
International Media Enquiries
Mark Swallow/David Dible (Citigate Dewe Rogerson)
Tel: +44-207-638-9571
Email: nordicnanovector@citigatedewerogerson.com
About Nordic Nanovector
Nordic Nanovector is committed to develop and deliver innovative
therapies to patients to address major unmet medical needs and
advance cancer care. The Company aspires to become a leader in the
development of targeted therapies for haematological cancers.
Nordic Nanovector's lead clinical-stage candidate is Betalutin®, a
novel CD37-targeting antibody-radionuclide-conjugate designed to
advance the treatment of non-Hodgkin's lymphoma (NHL). NHL is an
indication with substantial unmet medical need, representing a
growing market forecast to be worth nearly USD 29 billion by 2026. Nordic Nanovector intends
to retain marketing rights and to actively participate in the
commercialisation of Betalutin® in core markets. Further
information can be found at www.nordicnanovector.com
Forward-looking statements
This press release contains certain forward-looking statements.
These statements are based on management's current expectations and
are subject to uncertainty and changes in circumstances, since they
relate to events and depend on circumstances that will occur in the
future and which, by their nature, will have an impact on Nordic
Nanovector's business, financial condition and results of
operations. The terms "anticipates", "assumes", "believes", "can",
"could", "estimates", "expects", "forecasts", "intends", "may",
"might", "plans", "should", "projects", "targets", "will", "would"
or, in each case, their negative, or other variations or comparable
terminology are used to identify forward-looking statements. These
forward-looking statements are not historic facts. There are a
number of factors that could cause actual results and developments
to differ materially from those expressed or implied in the
forward-looking statements. Factors that could cause these
differences include, but are not limited to, risks associated with
implementation of Nordic Nanovector's strategy, risks and
uncertainties associated with the development and/or approval of
Nordic Nanovector's product candidates, ongoing and future clinical
trials and expected trial results, the ability to commercialise
Betalutin®, technology changes and new products in Nordic
Nanovector's potential market and industry, Nordic Nanovector's
freedom to operate (competitors patents) in respect of the products
it develops, the ability to develop new products and enhance
existing products, the impact of competition, changes in general
economy and industry conditions, and legislative, regulatory and
political factors. No assurance can be given that such expectations
will prove to have been correct. Nordic Nanovector disclaims any
obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or
otherwise.
This information is subject to a duty of disclosure pursuant to
Section 5-12 of the Securities Trading Act.
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/nordic-nanovector/r/nordic-nanovector-appoints-dr-gabriele-elbl-as-vice-president-global-regulatory-affairs,c2921883
View original
content:http://www.prnewswire.com/news-releases/nordic-nanovector-appoints-dr-gabriele-elbl-as-vice-president-global-regulatory-affairs-300928364.html
SOURCE Nordic Nanovector